Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
retinal vein occlusion
Pharma
Roche's juggernaut Vabysmo routs analyst consensus
In the first quarter, Roche's Vabysmo racked up sales of 847M Swiss francs, which was up 108% and demolished analysts' consensus.
Kevin Dunleavy
Apr 24, 2024 11:29am
Roche's Vabysmo snares FDA nod to treat retinal vein occlusion
Oct 27, 2023 11:07am
Roche's Vabysmo shows durability in retinal vein occlusion
Oct 10, 2023 10:21am
Roche's Vabysmo shows an edge over Eylea in retina drying
Feb 10, 2023 10:06am
Roche touts Vabysmo toe-to-toe data against Eylea in RVO
Oct 27, 2022 10:55am
